[Survival Analysis of 148 Patients with Primary Diffuse Large B Cell Lymphoma]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Feb;27(1):61-66. doi: 10.7534/j.issn.1009-2137.2019.01.010.
[Article in Chinese]

Abstract

Objective: To investigate the clinical outcome of the patients with primary diffuse large B-cell lymphoma(DLBCL).

Methods: Clinical data of 148 patients with DLBCL in our hospital and cancer hospital from March 2006 to April 2016 were retrospectively analyzed. Kaplan-Meier analysis was used to estimate progression-free survival(PFS)and overall survival(OS).

Results: 5-year OS and PFS rates were 85% and 69%,respectively. The survival analysis showed that 5-year OS rate of R-CHOP group was significantly higher than that of CHOP alone group(89% vs. 70%,P<0.05). In univariate analysis,several clinical factors,such as older age(>60 years),poor ECOG score(≥2),advanced stage(Ⅲ-Ⅳ),higher IPI score(≥3),CHOP alone and absence of radiotherapy related with poor survival rate. Furthermore,multivariate analysis showed that age>60 year significantly related with the worse OS.

Conclusion: Age >60 year is an important independent prognostic factor to predict worse OS or PFS.

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols
  • Cyclophosphamide
  • Disease-Free Survival
  • Doxorubicin
  • Humans
  • Lymphoma, Large B-Cell, Diffuse*
  • Prognosis
  • Retrospective Studies

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Doxorubicin
  • Cyclophosphamide